Egfr soluble isoforms and their transcripts are expressed in meningiomas

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Guillaudeau, Angélique ^a   Durand, Karine ^a   Bessette, Barbara ^a   Chaunavel, Alain ^a   Pommepuy, Isabelle ^a   Projetti, Fabrice ^a   Robert, Sandrine ^a   Caire, François ^a   Rabinovitch Chable, Hélène ^a   Labrousse, François ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ISOPROTEIN;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURGERY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MENINGIOMA; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; ALTERNATIVE RNA SPLICING; FRANCE; KAPLAN MEIER METHOD; MENINGIOMA; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MENINGIOMA; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84862075872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037204     Document Type: Article

References (79)

1. Whittle IR, Smith C, Navoo P, Collie D, (2004) Meningiomas. Lancet 363: 1535-1543.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
3. Arteaga CL, (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32S-40S.
4. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, et al. (1994) The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41-49.
5. Guillaudeau A, Durand K, Rabinovitch-Chable H, Pommepuy I, Mesturoux L, et al. (2011) Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain. Int J Oncol 40: 1142-1152.
6. Stewart CJ, Owens OJ, Richmond JA, McNicol AM, (1992) Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 11: 266-272.
7. Albanell J, Gascon P, (2005) Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 6: 259-274.
8. Mendelsohn J, Baselga J, (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
9. Modjtahedi H, (2005) Molecular therapy of head and neck cancer. Cancer Metastasis Rev 24: 129-146.
10. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS, (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21.
11. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, et al. (2008) Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 314: 2907-2918.
12. Rose-John S, Heinrich PC, (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300 (Pt 2): 281-290.
13. Lafky JM, Wilken JA, Baron AT, Maihle NJ, (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785: 232-265.
14. Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ, (2011) Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and alpha5-integrin. Biochemistry 50: 4309-4321.
15. Reiter JL, Maihle NJ, (1996) A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res 24: 4050-4056.
16. Flickinger TW, Maihle NJ, Kung HJ, (1992) An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol 12: 883-893.
17. Ilekis JV, Stark BC, Scoccia B, (1995) Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol Reprod Dev 41: 149-156.
18. Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, et al. (2001) Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 71: 1-20.
19. Ancot F, Foveau B, Lefebvre J, Leroy C, Tulasne D, (2009) Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity. Oncogene 28: 2185-2195.
20. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, et al. (2008) Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 103: 1783-1797.
21. Hunts JH, Shimizu N, Yamamoto T, Toyoshima K, Merlino GT, et al. (1985) Translocation chromosome 7 of A431 cells contains amplification and rearrangement of EGF receptor gene responsible for production of variant mRNA. Somat Cell Mol Genet 11: 477-484.
22. Oh MJ, Choi JH, Kim IH, Lee YH, Huh JY, et al. (2000) Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6: 4760-4763.
23. Zampino MG, Magni E, Santoro L, Zorzino L, Dell'Orto P, et al. (2008) Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib? Cancer Chemother Pharmacol 63: 139-148.
24. Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, et al. (2009) Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Cancer Treat Res 149: 189-202.
25. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, et al. (2001) A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev 10: 1175-1185.
26. Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ, (2009) Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs 12: 302-308.
27. Muller V, Witzel I, Pantel K, Krenkel S, Luck HJ, et al. (2006) Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res 26: 1479-1487.
28. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, et al. (2011) Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer. Clin Cancer Res 17: 5501-5512.
29. Maramotti S, Paci M, Miccichè F, Ciarrocchi A, Cavazza A, et al. (2011) Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung cancer 15 [Epub ahead of print].
30. Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, et al. (2010) Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev 19: 982-991.
31. Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, et al. (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87: 315-323.
32. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, et al. (2010) Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol 5: 46.
33. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW, (2007) Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg 106: 1034-1040.
34. Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, et al. (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108: 135-142.
35. Johnson MD, Horiba M, Winnier AR, Arteaga CL, (1994) The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. Hum Pathol 25: 146-153.
36. Jones NR, Rossi ML, Gregoriou M, Hughes JT, (1990) Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66: 152-155.
37. Linggood RM, Hsu DW, Efird JT, Pardo FS, (1995) TGF alpha expression in meningioma-tumor progression and therapeutic response. J Neurooncol 26: 45-51.
38. Sanfilippo JS, Rao CV, Guarnaschelli JJ, Woost PG, Byrd VM, et al. (1993) Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. Surg Gynecol Obstet 177: 488-496.
39. Weisman AS, Raguet SS, Kelly PA, (1987) Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 47: 2172-2176.
40. Chaffanet M, Chauvin C, Laine M, Berger F, Chedin M, et al. (1992) EGF receptor amplification and expression in human brain tumours. Eur J Cancer 28: 11-17.
41. Westphal M, Herrmann HD, (1986) Epidermal growth factor-receptors on cultured human meningioma cells. Acta Neurochir (Wien) 83: 62-66.
42. Mathieu A, Weynand B, Verbeken E, Da Silva S, Decaestecker C, et al. (2010) Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 69: 46-50.
43. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96: 211-217.
44. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD, (2010) Medical therapies for meningiomas. J Neurooncol 99: 365-378.
45. Gan HK, Kaye AH, Luwor RB, (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16: 748-754.
46. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, et al. (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53: 3217-3220.
47. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539.
48. Simpson D, (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20: 22-39.
49. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
50. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P, (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8: 433-443.
51. van Dijk MC, Rombout PD, Boots-Sprenger SH, Straatman H, Bernsen MR, et al. (2005) Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol 14: 9-16.
52. Guillaudeau A, Durand K, Pommepuy I, Robert S, Chaunavel A, et al. (2009) Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol 17: 220-226.
53. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, et al. (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118: 1173-1180.
54. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807.
55. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S, (2005) Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103: 630-636.
56. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, et al. (2008) Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol.
57. Varella-Garcia M, (2006) Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 1: 19.
58. Fiore DC, Pasternak AV, (2010) Radwan RM Pain in the quiet (not red) eye. Am Fam Physician 82: 69-73.
59. Horsfall DJ, Goldsmith KG, Ricciardelli C, Skinner JM, Tilley WD, et al. (1989) Steroid hormone and epidermal growth factor receptors in meningiomas. Aust N Z J Surg 59: 881-888.
60. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T, (2010) determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 103: 1765-1772.
61. Domingo G, Perez CA, Velez M, Cudris J, Raez LE, et al. (2010) EGF receptor in lung cancer: a successful story of targeted therapy. Expert Rev Anticancer Ther 10: 1577-1587.
62. Markman B, Javier Ramos F, Capdevila J, Tabernero J, (2010) EGFR and KRAS in colorectal cancer. Adv Clin Chem 51: 71-119.
63. Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR, (2010) The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol 102: 353-366.
64. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 1731-1745.
65. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, et al. (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 107: 2616-2621.
66. Nagane M, Lin H, Cavenee WK, Huang HJ, (2001) Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162 Suppl pp. S17-S21.
67. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
68. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, et al. (2007) EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep 17: 319-323.
69. Rahimi M, Toth TA, Tang CK, (2011) CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Lett 306: 43-51.
70. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, et al. (2007) Targeting EGFR in bladder cancer. World J Urol 25: 573-579.
71. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, et al. (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257.
72. Kong YG, Su CB, Ren ZY, Wang RZ, (2002) [Measurement of epidermal growth factor receptor concentration in the pre- and postoperative serum in patients with meningiomas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 427-429.
73. Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, et al. (2010) EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer 9: 166.
74. Basu A, Raghunath M, Bishayee S, Das M, (1989) Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol 9: 671-677.
75. Weber W, Gill GN, Spiess J, (1984) Production of an epidermal growth factor receptor-related protein. Science 224: 294-297.
76. Cadena DL, Gill GN, (1993) Expression and purification of the epidermal growth factor receptor extracellular domain utilizing a polycistronic expression system. Protein Expr Purif 4: 177-186.
77. Greenfield C, Hiles I, Waterfield MD, Federwisch M, Wollmer A, et al. (1989) Epidermal growth factor binding induces a conformational change in the external domain of its receptor. Embo J 8: 4115-4123.
78. Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, et al. (2011) Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem 18: 1599-1612.
79. You B, Chen EX, (2011) Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. J Clin Pharmacol.